What’s New in Large Vessel Vasculitis

This study did not address whether patients with Takayasu arteritis and a spondyloarthritis-spectrum disorder need to be treated more aggressively, although it did note a higher rate of biologic use among these patients. However, this study implies that it may be worthwhile to screen patients with Takayasu arteritis for evidence of inflammatory bowel disease, psoriasis, and ankylosing spondylitis, although the absolute frequency of overlap between Takayasu arteritis and HLA-B27 associated diseases is low.

Philip Seo, MD, MHS, is an associate professor of medicine at Johns Hopkins University School of Medicine. He served as the third physician editor of The Rheumatologist.

Author’s note: The 22nd International Vasculitis Workshop will be hosted by the Australia and New Zealand Vasculitis Society Feb. 21–25, 2026, in Melbourne, Australia.

References

1. Abstracts book, version 3. 21st International Vasculitis Workshop. 2024 Apr 5.
2. Redmond C, Zorc R, Sylvester M, et al. Impact of IL-6 receptor small nucleotide polymorphism Asp358Ala on T cell activity and clinical outcomes in patients with giant cell arteritis [abstract]. Arthritis Rheumatol. 2023;75(suppl 9).
3. Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: Apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995 Aug 1;123(3):192–194.
4. Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024;83:741–751.